Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494467 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Papulopustular Rosacea Study
A Phase 3 study of Papulopustular Rosacea, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 688
- Enrollment target
- 20
- Study locations
NCT01494467 is a Phase 3 study of Papulopustular Rosacea that has completed, run by Galderma R&D. The registered enrollment target is 688 participants, above the 217-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (217% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT01494467, a Phase 3 study of Papulopustular Rosacea, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 688 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.
Conditions Studied
Interventions
- DRUG CD5024
- DRUG Azelaic acid 15% Gel
Study Locations (20)
California
- Dermatology Specialists, Inc - Oceanside
- Integrated Research Group, Inc - Riverside
- Therapeutics Clinical Research - San Diego
- University of California, San Francisco - San Francisco
- ATS Clinical Research - Santa Monica
- Redwood Dermatology Research - Santa Rosa
Alabama
- Total Skin and Beauty - Birmingham
- Coastal Clinical Research, Inc. - Mobile
Florida
- FXM Research Corp Miami - Miami
- Leavitt Medical Associates of Florida dba Ameriderm Research - Ormond Beach
Georgia
- Atlanta Dermatology, Vein & Research Center, LLC - Alpharetta
- Emory University - Atlanta
Illinois
- Altman Dermatology Associates - Arlington Heights
- Northwestern University - Chicago
Indiana
- Deaconess Clinic, Inc. - Evansville
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Arkansas
- Burke Pharmaceutical Research - Hot Springs
Kentucky
- Dermatology Specialists Research - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 688 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01494467
The ClinicalTrials.gov registry entry for NCT01494467 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 688 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (217% higher). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Papulopustular Rosacea appearing as the primary indexed condition, and to 2 interventions - of which CD5024 is the first listed.
NCT01494467 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT01494467 about?
NCT01494467 is a clinical study titled "Phase 3 Papulopustular Rosacea Study". The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.
What is the current status of trial NCT01494467?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 688 participants. The study started on 2011-12. Estimated completion is 2013-08.
What conditions does trial NCT01494467 study?
This clinical trial studies the following conditions: Papulopustular Rosacea.
What interventions are being tested in trial NCT01494467?
The interventions under investigation include: CD5024 (DRUG), Azelaic acid 15% Gel (DRUG).
Who is sponsoring clinical trial NCT01494467?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01494467 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papulopustular Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
COMPLETED · Phase 3
-
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
COMPLETED · Phase 3
-
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
COMPLETED · Phase 3
-
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
RECRUITING · Phase 2
-
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
COMPLETED · Phase 1
-
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.